Company profile
Neurogene Inc.
NASDAQ: NGNE · Healthcare · Biotechnology
#1166 of 1,422 Healthcare companies by revenuebottom-decile growth
EA Score
43DFH 60DQ 33GM 0SS 67
v0.1 · 65/100 weight · provisional
↑ balance-sheet leverage, Altman-Z · ↓ revenue growth (YoY), 3-yr revenue growth
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
-100.0%
Net income (FY)
-$90.4M
Employees
131
as of 2026-08-11
Market cap
$577.6M
as of 2026-08-11
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02025
Net income-$90.4M-$90.4M2025
Operating income-$103.3M-$103.3M2025
Total assets$288.6M$288.6M2025
Liabilities$23.7M$23.7M2025
Equity$264.9M$264.9M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY24
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
Reportable100%
By geography
Not disclosed.
The read
What is Neurogene Inc.’s revenue?
Neurogene Inc. booked $0 in FY2025 revenue, contracting 100% year over year — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Monopar Therapeutics Inc.59CAllogene Therapeutics, Inc.39DAchieve Life Sciences, Inc.37DArtiva Biotherapeutics, Inc.41DContineum Therapeutics, Inc.57CNika Pharmaceuticals Inc.29DNeighbors
New York →Key facts
CEORachel L. McMinn
SectorHealthcare
IndustryBiotechnology
HeadquartersNew York City, NY
ExchangeNASDAQ: NGNE
Employees131
IPO date2014-03-07
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.